Skip to main content
. Author manuscript; available in PMC: 2013 Aug 28.
Published in final edited form as: Med Sci Sports Exerc. 2012 Mar;44(3):371–376. doi: 10.1249/MSS.0b013e318234316f

TABLE 1.

Demographic and clinical characteristics of subjects at baseline.

Characteristic All Patients in Analysis (N = 767)
Age (yr), median (25th–75th percentile) 57 (49–66)
Female, n (%) 227 (30)
Race, n (%)
 White 445 (59)
 Black 265 (35)
 Other 48 (6)
Resting systolic blood pressure (mmHg), median (25th–75th percentile) 112 (102–128)
Resting diastolic blood pressure (mmHg), median (25th–75th percentile) 70 (62–80)
Resting seated HR before exercise test (beats•min−1), median (25th–75th percentile) 69 (61–77)
Weight (kg), median (25th–75th percentile) 91 (77–108)
Body mass index (kg•m−2), median (25th–75th percentile) 30 (26–36)
Left ventricular ejection fraction (%), median (25th–75th percentile) 25 (21–31)
History of diabetes, n (%) 251 (33)
History of stroke, n (%) 68 (9)
History of hypertension, n (%) 454 (60)
Etiology of HF, ischemic, n (%) 375 (49)
New York Heart Association Functional Class, n (%)
 II 557 (73)
 III/IV 210 (27)
Number of HF hospitalizations in previous 6 months, n (%)
 0 568 (74)
 1 152 (20)
 2+ 42 (5)
Peak exercise HR (beats•min−1), median (25th–75th percentile) 125 (111–140)
Peak oxygen uptake (mL•kg−1•min−1), median (25th–75th percentile) 15.7 (12.5–19.0)
Peak RER, median (25th–75th percentile) 1.13 (1.09–1.19)
Peak RPE (Borg, 6-20), median (25th–75th percentile) 17 (15–19)
Prior coronary artery bypass graft surgery, n (%) 154 (20)
Prior percutaneous coronary intervention, n (%) 161 (21)
Prior myocardiac infarction, n (%) 318 (41)
History of atrial fibrillation/flutter, n (%) 71 (9)
History of peripheral vascular occlusive disease, n (%) 39 (5)
History of depression, n (%) 152 (20)
Angiotension-coverting enzyme inhibitor, n (%) 584 (76)
Dose of β-adrenergic blocking agent, carvedilol equivalents (mg•d−1), median (25th–75th percentile) 40 (25–50)